ADA
<ѻý class="page-description">American Diabetes Associationѻý>Many also had adrenal abnormalities
Adolescence is a critical period in T1D, associated with hyperfiltration and high HbA1c levels
Randomized trial failed to get anywhere near tight glucose control
Phase II data support testing pemvidutide for comorbid obesity and liver conditions
Insulin sensitivity also improved in people with obesity free of diabetes
SECURE-T2D trial provides pivotal findings to expand use of the Omnipod 5 System
INHALE 3 provides insights into dosing and who might actually do worse than with a pump
Randomized trial shows a benefit of an inexpensive cholesterol drug
Zepbound met primary and secondary endpoints, with or without CPAP
Advance of disease driven by high BMI, with social determinants of health playing a role
Endocrinologists urged to pay attention to COORDINATE trial
But GI side effects higher than other comparable anti-obesity agents
Once-weekly CagriSema reduced body weight more than either agent alone
-
Obesity Week: The Obesity Society
November 2024
-
EASD: European Association for the Study of Diabetes
September 2024
-
ENDO: The Endocrine Society
June 2024
-
AACE: American Association of Clinical Endocrinology
May 2024